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Glycogen phosphorylase (GP) is an important target for the development of new anti-
hyperglycaemic agents. Flavonoids are novel inhibitors of GP, but their mode of action is 
unspecific in terms of the GP binding sites involved. Towards design of synthetic flavonoid 
analogues acting specifically at the inhibitor site and to exploit the site’s hydrophobic pocket, 
chrysin has been employed as a lead compound for the in silico screening of 1169 new 
analogues with different B ring substitutions. QM/MM-PBSA binding free energy calculations 
guided the final selection of eight compounds, subsequently synthesised using a Baker-
Venkataraman rearrangement-cyclisation approach. Kinetics experiments against rabbit 
muscle GPa and GPb together with human liver GPa, revealed three of these compounds (11, 
20 and 43) among the most potent that bind at the site (Ki s < 4 µM for all three isoforms), and 
more potent than previously reported natural flavonoid inhibitors. Multiple inhibition studies 
revealed binding exclusively at the inhibitor site. The binding is synergistic with glucose 
suggesting that inhibition could be regulated by blood glucose levels and would decrease as 
normoglycaemia is achieved. Compound 43 was an effective inhibitor of glycogenolysis in 
hepatocytes (IC50 = 70 µM), further promoting these compounds for optimization of their drug-
like potential. X-ray crystallography studies revealed the B-ring interactions responsible for 
the observed potencies.  
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Type 2 Diabetes (T2D) is a chronic heterogeneous disease characterised by hyperglycaemia. 
Its prevalence has been rising rapidly, but particularly in low- and middle-income countries 
[1]. T2D is characterized as a disorder of insulin secretion, insulin resistance and by increased 
production of hepatic glucose. Glycogenolysis may account for more than 70% of the hepatic 
glucose production. Additionally, a substantial amount of glucose from gluconeogenesis is 
cycled through the glycogen pool prior to efflux from the liver cells [2, 3]. The rate-determining 
enzyme in the glycogenolysis pathway is glycogen phosphorylase (GP; EC 2.4.1.1), rendering 
GP a very promising and validated target for the development of much needed more effective 
T2D treatments [4]. However, GP inhibition has also been recognised as having significant 
potential for the treatment of other conditions such as cancer, myocardial and cerebral 
ischemias [5-7].  
GP is an allosteric enzyme and has a number of different binding sites [8]: the catalytic, 
allosteric, new allosteric, inhibitor, quercetin binding,[9] benzimidazole[10] and the glycogen 
storage sites. It exists in two interconvertible forms, the phosphorylated GPa form which is the 
predominantly active R state and with high substrate affinity, and the unphosphorylated GPb 
form which is the predominantly inactive T state (low substrate affinity) [4]. Phytogenic 
chemicals are a promising source of compounds with the potential to inhibit GP [11, 12]. 
Natural flavonoids have been revealed as a good source of GP inhibitors in a number of studies 
[13-16], which have recently been reviewed [11, 12]. They are ubiquitous components of fruit 
and vegetables and are consumed in our daily diets.  Significantly, studies in diabetic and non-
diabetic rats have shown that the anti-hyperglycaemic properties of flavonoids are due to their 
effect on glycogen metabolism [17-19]. Jakobs et al. extensive study of 24 flavonoids 
demonstrated that most of the compounds investigated inhibited rabbit muscle GPa (rmGPa), 
and that inhibition of GPa was two to four times better than for rmGPb [13]. This inhibition of 
the active GPa form is favourable in terms of potential for blood glucose regulation in T2D 
patients.  
Structurally, flavonoids have a general scaffold consisting of two aromatic rings (A and B), 
linked by three carbon atoms that are usually in a heterocyclic ring (C) with oxygen (c.f. 
chrysin, Figure 1). The differences in ring C leads to the structural classification of flavonoids 
as flavones, flavanols, flavanones, anthocyanidins and isoflavonoids [11]. The best flavonoid 
inhibitors of GP are on the low µM range, some of which are shown in Figure 1.  These include 
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the flavonols quercetin  and quercetagetin; flavones such as 6-hydroxyluteolin and chrysin. 
Certain anthocyanidins such as cyanadin and catechins such as epigallocatechin gallate 
(EGCG), are also potent inhibitors. However, the inhibitory potential of different flavonoids is 








   
Chrysin quercetin quercetagetin 
IC50(GPa) = 27.5 [13] IC50(GPa) = 4.8 [13] IC50(GPb) = 9.7 [14], (3.5(Ki)) [14] 
IC50 (GPb) = 15.3 [13], (19.01 
(Ki)) [16] 
IC50(GPb) = 20.9 [13], 33.5 [14] Binding site: allosteric 
Binding site: inhibitor site 
 








6-hydroxyluteolin cyanidin EGCG 
IC50(GPb) = 11.6 [13] IC50(GPa) = 3.0 [13] IC50(GPa) = 7.7 [13] 
Binding site: unknown IC50(GPb) = 9.0 [13] IC50(GPb) = 33.9 [13], 34.0 [20] 
 
Binding site: unknown Binding site: unknown 
   
Flavopiridol flavopiridol analogue flavopiridol analogue 
Ki (GPb) = 1.16 [21], 1.24 [16] Ki (GPb) = 1.28[22]  Ki (GPb) = 0.83[22]  






Figure 1. Inhibition constants (µM) for some of the most potent natural flavonoid inhibitors of 
glycogen phosphorylase known to date together with their inhibition data and binding sites. 
The flavonoid ring labels A-C and atom numbering scheme used throughout text is shown for 
chrysin. Also displayed is the synthetic flavonoid derivative flavopiridol, together with two of 
its analogues. (* = assumed binding site). The GPb dimer is also shown with the various 
binding sites indicated.  
Previously it was assumed that flavonoids may display their inhibitory potential of GP by a 
similar mode of action. However, it is now evident from recent studies [9, 14-16] that their 
binding site is dependent on the flavonoid specific substitution patterns, more specifically the 
presence or absence of different hydroxyl groups. Indeed, the GP binding site of most 
flavonoids is unknown [11]. However, the binding of chrysin to GP has been studied in detail; 
its solved crystal structure complex with rmGPb revealed binding exclusively at the inhibitor 
site [16].  
The inhibitor site of GP, also known as the caffeine (Ki ~ 0.1 mM [23, 24]) binding site, is 
found on the surface of the enzyme, approximately 12 Å from the catalytic site. When the 
enzyme is in the less active T state, Phe285, from the 280s loop (residues 282-287) is stacked 
close to Tyr613, from the α19 helix (residues 613-631). These two aromatic residues form the 
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core of the inhibitor site. The ligands that bind to this site are considerably influenced by these 
residues due to the potential for an inhibitor to form a sandwich-like complex with GP, 
exploiting π-stacking interactions with both Phe285 and the Tyr613 sidechains (Fig. 2). This 
promotes the T state conformation of the enzyme via stabilisation of the closed conformation 
of the 280s loop, which in turn blocks access to the catalytic site. Inhibition of the binding site 
generally acts synergistically with glucose, which suggests that inhibition could be regulated 
by blood glucose levels, and would decrease as normoglycaemia is achieved without causing 
hypoglycaemia.[25]  Because of this property, design of inhibitors targeting the site is 
particularly attractive from a drug design perspective. The most potent reported inhibitor 
binding at the site is flavopiridol (Figure 1; Ki ~ 1.2 µM [16, 21]) with slightly better inhibition 
obtained in a study of its analogues (best Ki = 0.83 µM) [22]. Natural products such as 
flavonoids provide scaffolds for design of potent GP inhibitors but the only flavonoid ligand 
confirmed to bind at the site is chrysin, with a previously reported Ki of 19.01 µM [16].                                                      
                   
Figure 2. Binding of chrysin at the inhibitor site of rmGPb (PDB entry: 3EBO[16]) 
highlighting the key π-stacking interactions involved with residues Phe285 and Tyr613 and 
also the hydrophobic pocket key residues Ile380, Tyr573 and Phe771 in close proximity to the 
phenyl ring B of chrysin. 
Of particular importance to binding of flavonoids at this site is a hydrophobic pocket lined by 
Ile380, Tyr573 and Phe771, as highlighted in Fig. 2. We have previously proposed that 
flavonoids with ring B polar OH substituents (in particular at position 4’) are unfavourable for 
inhibitor site binding on the basis of quantum mechanics – molecular mechanics/Poisson 
Boltzmann surface area (QM/MM-PBSA) binding free energy (BFE; ∆𝐺𝑏𝑖𝑛𝑑) calculations 
7 
 
[16]. It was demonstrated that quercetagetin with 3’ and 4’ OH substituents (Fig. 1) displayed 
poor binding at the site based on its calculated binding affinity, and this was in agreement with 
multiple inhibition studies proposing allosteric site binding [14]. This theory was further 
validated by the subsequent discovery of the quercetin binding site (PDB entry 4MRA) 
discovered through the screening of polyphenolic extracts from the vinification byproducts of 
Vitis vinifera [9]. These binding features have motivated the current work to design more potent 
synthetic flavonoid analogues of the lead compound chrysin with different ring B that act 
specifically at the inhibitor site. 
In this paper, we present the virtual screening of a library of 1169 compounds exploiting the 
ZINC database (http://zinc.docking.org)[26] using chrysin as the lead compound and its 7-
dihydroxy-4H-chromen-4-one moiety as the core scaffold for the design of more effective B 
ring substituents (Fig. 3). Initial screening was performed using Glide docking [27] in both 
standard (Glide-SP) and extra precision (Glide-XP) modes but combining the results in a 
consensus approach both in terms of predicted binding affinities [28, 29] and binding modes 
[30], aimed at reducing the number of false positive predictions. The top-ranked predicted 
compounds considered to be synthetically viable were then post-processed using QM/MM-
PBSA binding free energy calculations. Eight candidates were selected for synthesis and 
extensive kinetics studies performed. Crystallographic studies revealed the interactions that 
govern the observed potencies. Additionally, the effectiveness of the most potent inhibitor for 











Figure 3. The 7-dihydroxy-4H-chromen-4-one moiety of chrysin and the benzoyl chloride 
substructure hits from searching the ZINC docking database[26] were combined using 
CombiGlide to yield the final set of 1169 ligands for virtual screening. 
 
2. Results and Discussions 
2.1 In Silico Screening 
The aim of the calculations was to screen 5,7-dihydroxyflavones for favourable substitutions 
on ring B. Using the ZINC database [26] and CombiGlide program [27], we generated 1169 
unique ligands for initial docking calculations (Fig. 3). The ligands were docked to two models 
of GPb, model 1 from its solved crystallographic complex with chrysin (PDB entry 3EBO[16]) 
and model 2, an induced-fit docking GPb model for the predicted complex with 5,7-dihydroxy-
2-(naphthalen-2-yl)-4H-chromen-4-one  (B phenyl ring of chrysin substituted by a 2-
naphthalene group). The latter model aimed to refine the hydrophobic pocket region to accept 
larger B ring substituents (Fig. 2). For each protein model, the ligands were docked using both 
Glide-SP and –XP [27], and the predicted potency ranks from each method combined using 
consensus scoring. Additional consensus of the Glide-SP and –XP docking poses in terms of 
ligand binding modes was used to further filter ligands, as described in the experimental 


















approach predicted 79 and 257 analogues as more potent than chrysin using models 1 and 2, 
respectively. As anticipated, model 2 allowed larger substituents on the B ring to occupy a more 
open hydrophobic pocket.  
End point methods such as MM-PB(GB)SA are an effective post-docking strategy for the 
calculation of binding free energies [31]. QM/MM-PB(GB)SA methods, however, are gaining 
more prominence due to potential for better description of binding site interactions using QM 
methods [32-35], and have previously been successfully applied to flavonoid binding at the GP 
inhibitor site where a QM description was necessary to describe the π-stacking interactions of 
ligands with residues Phe285 and Tyr613 [16]. Here, preliminary QM/MM-PBSA calculations 
on the top-ranked 200 ligands from docking for each of model 1 and model 2 were performed. 
Protein-ligand complex geometries that gave ∆𝐺𝑏𝑖𝑛𝑑 values < -11 kcal/mol  (a threshold chosen 
based on its proximity to the ∆𝐺𝑏𝑖𝑛𝑑 value of -12.35 kcal/mol for chrysin) were refined using 
Prime 4.2 [27] (58 ligands) before a final set of QM/MM-PBSA binding free energy 
calculations. As expected, the final ∆𝐺𝑏𝑖𝑛𝑑 values were lower for these optimized complex 
structures and 36 analogues were predicted as more potent than the lead compound chrysin (-
14.12 kcal/mol) (Table 1).  
Analysis of the 36 flavonoid derivatives in Table 1 revealed 12, 22 and 2 ligands having mono-
, di- and tri-substituted B rings, respectively. These substitutions are mainly in the B ring ortho 
(21 ligands) and meta (25 ligands) positions, with 10 ligands having para substitutions. The 
majority of substitutions are with halogens (28 ligands), particularly with fluorine (15 ligands). 
5 ligands have di-fluoro B ring substitutions. Fluorine is widely used in the lead optimization 
phase of drug design projects due to its potential to enhance drug-like properties such as 
permeability [36]. This has particular significance for flavonoids where oral bioavailability 
remains one of the most critical issues for their role in nutrition and health [37]. 10, 9 and 2 
derivatives contained one Cl, Br or I substituent, respectively. A smaller size halogen, 
therefore, appeared to be potentially more favourable. One compound had di-chloro 
substitutions (meta- and para-positions). Other B ring substituents for the 36 compounds were 
methyl (2 ligands), amine (2 ligands), aldehyde (CHO) group (1 ligand) and hydroxyl (7 
ligands).  
Analysing the breakdown of ∆𝐺𝑏𝑖𝑛𝑑 (Eq.(1); c.f. Experimental Section) for the top 36 ligands 
(Table 1), the ∆𝐸𝑄𝑀/𝑀𝑀 values representing the gas phase interaction energy values dominate 
with values between -55.03 and -79.51 kcal/mol. The strongest ∆𝐸𝑄𝑀/𝑀𝑀 interactions 
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(compound 16) have polar hydroxyl groups in the 2’ and 3’ positions; the corresponding least 
favourable (compound 29) has fluorine at the meta positions (3’ and 5’). For ligands that are 
halogen substituted only, the best ∆𝐸𝑄𝑀/𝑀𝑀 values are -60.71 kcal/mol for compound 10 with 
fluorine (3’) and bromine (4’) substitutions, and -59.63 kcal/mol for compound 11 with fluorine 
(3’) and chlorine (4’) substitutions. However, more favourable ∆𝐸𝑄𝑀/𝑀𝑀 values generally had 
less favourable solvation free energy changes (∆𝐺𝑠𝑜𝑙𝑣) values (range of +21.23 – +45.77 
kcal/mol). The larger desolvation penalties were associated with the more polar groups, as 
demonstrated by the larger polar contributions to the solvation free energy changes (∆𝐺𝑠𝑜𝑙𝑣
𝑃𝐵  
term, predominantly electrostatic solvation enthalpy effects). ∆𝐺𝑠𝑜𝑙𝑣
𝑃𝐵  values ranged from 
+26.09 (compound 1) to +50.38 kcal/mol (compound 16). Meanwhile, the non-polar 
contributions (∆𝐺𝑠𝑜𝑙𝑣
𝑆𝐴 ) to the solvation free energy changes were small and similar for all 
ligands (range -4.39 – -5.11 kcal/mol). A sensitive balance between ∆𝐸𝑄𝑀/𝑀𝑀 and ∆𝐺𝑠𝑜𝑙𝑣 for 
the identification of new potent inhibitors was therefore observed. For example, compound 16 
with 2’ and 3’ OH substitutions had the most favourable ∆𝐸𝑄𝑀/𝑀𝑀 value (-79.51 kcal/mol) but 
the least favourable ∆𝐺𝑠𝑜𝑙𝑣 value (+45.77 kcal/mol) and was ranked sixteen; ligand (1) with a 
4’ Br substitution had the least desolvation penalty (∆𝐺𝑠𝑜𝑙𝑣= 21.23 kcal/mol) but much less 
favourable ∆𝐸𝑄𝑀/𝑀𝑀 value (-59.29 kcal/mol) yet was ranked first. Entropy changes, TΔS, on 
the other hand had a range of just ~ 2 kcal/mol (-13.37 to -15.99 kcal/mol) and did not influence 
as much the ligand rankings.     
Considering synthetic viability as well as the availability of reagents, eight compounds were 
selected for synthesis and subsequent experimental validation, none of which gave warnings 
for Pan Assay Interference Compounds  (PAINS) [38], as determined using the ZINC on-line 
filter (http://zinc15.docking.org/patterns/home/). Predicted inhibitors ranked 1 (4’ = Br) and 2 
(2’ = OH) were chosen, together with fluoro-substituted 9 (3’ = F) and 20 (4’ = F). Two di-
substituted ligands ranked 10 (3’ = Br; 4’ = F), and 11 (3’ = Cl; 4’ = F) were also selected. 
Although not in the top 36, we additionally chose two other mono-substituted ligands with 
methyl substituents in the meta 3’ (43) and para 4’ positions (52). Their ∆𝐺𝑏𝑖𝑛𝑑 values were -
13.47 kcal/mol and -12.01 kcal/mol, respectively. They were ranked in ~ the top 50 from an 
initial 1169 ligands and their simple non-polar substituents considered to have potential to 





















𝑡𝑜𝑡𝑎𝑙  𝑇∆𝑆 ∆𝐺𝑏𝑖𝑛𝑑
 
  1* H H Br H H -59.29 26.09 -4.86 21.23 -14.69 -23.37  
  2* OH H H H H -70.83 38.18 -4.78 33.40 -14.69 -22.74  
3 Cl H H H H -57.88 27.20 -4.98 22.21 -13.85 -21.82  
4 F H H Br H -59.96 28.66 -4.93 23.73 -14.73 -21.50  
5 OH CH3 H H H -65.72 34.82 -4.96 29.86 -14.96 -20.89  
6 NH2 H H Cl H -65.65 35.80 -4.58 31.22 -15.14 -19.29  
7 Br H H H H -59.07 30.53 -4.55 25.98 -13.90 -19.18  
8 F H Cl H H -57.08 28.14 -4.69 23.45 -14.49 -19.13  
  9* H F H H H -56.08 28.45 -4.76 23.69 -13.37 -19.02  
  10* H Br F H H -60.71 32.43 -5.14 27.29 -14.55 -18.87  
  11* H Cl F H H -59.63 31.45 -4.79 26.66 -14.24 -18.73  
12 F H F H H -57.21 29.59 -4.47 25.13 -13.69 -18.39  
13 F H H I H -57.34 29.39 -5.06 24.33 -14.63 -18.38  
14 F H H Cl H -57.07 29.55 -4.95 24.60 -14.32 -18.15  
15 OH H H Cl H -71.17 43.26 -5.11 38.15 -15.24 -17.78  
16 OH OH H H H -79.51 50.38 -4.61 45.77 -15.99 -17.74  
17 H Cl Cl H H -59.11 32.04 -4.91 27.13 -14.79 -17.19  
18 H Cl H H H -56.89 30.59 -4.94 25.66 -14.11 -17.12  
19 H NH2 H H H -59.52 32.78 -4.69 28.09 -14.42 -17.01  
  20* H H F H H -59.04 32.80 -4.76 28.04 -14.07 -16.93  
21 H Br H F H -56.32 29.18 -4.42 24.76 -14.64 -16.92  
22 H Br H H H -57.31 31.07 -4.76 26.31 -14.11 -16.89 
23 F H H H H -56.43 30.63 -4.39 26.24 -13.64 -16.54 
24 H F F H H -58.70 33.86 -5.03 28.83 -14.00 -15.87 
25 F Br H H H -56.23 30.86 -4.73 26.13 -14.33 -15.76 
26 OH H Cl H H -71.56 45.10 -4.62 40.48 -15.43 -15.65 
27 H OH H OH H -71.88 46.16 -4.67 41.49 -14.86 -15.53  
28 F H H Br F -55.13 30.35 -4.92 25.43 -14.43 -15.27  
29 H F H F H -55.03 30.39 -4.60 25.79 -14.20 -15.03  
30 F H F CH3 H -59.81 34.58 -4.96 29.62 -15.33 -14.87 
31 F H H F H -56.20 32.22 -4.86 27.36 -13.98 -14.86  
32 Cl H H Br H -58.38 33.94 -4.85 29.09 -14.64 -14.65 
33 H OH H H H -70.06 45.21 -4.67 40.54 -15.07 -14.45 
34 CHO H H H H -58.52 34.48 -4.67 29.81 -14.36 -14.36 
35 F Cl H H H -55.62 31.98 -4.92 27.06 -14.27 -14.29  





In general, compounds 1, 9, 10, 11, 20, 43 and 52 were synthesised in four steps (Scheme 1) 
from commercially available starting materials. The synthetic process started with a union 
between 2’-hydroxy-4’,6’-dimethoxyacetophenone (A) and the benzoyl chloride of choice 
identified from the CombiGlide results (B), to yield ester (C) in good yields. A base-promoted 
Baker-Venkataraman rearrangement followed in which the aroyl group migrated from oxygen 
onto carbon giving rise to diketone (D). An acid catalysed cyclization reaction yielded the core 
flavonoid structure (E), which following demethylation, gave the desired products (F).  For the 
synthesis of compound 2 (R=2'-OH), the same sequence of steps were repeated (Scheme 1), 
but instead of using 2’-hydroxy-4’,6’-dimethoxyacetophenone (A), 2'-hydroxyacetophenone 
was used instead for a reaction with 2,4,6-trimethoxybenzoyl chloride. In this latter case, 
compound G was isolated as the product of step 3, which after treatment with hydroiodic 
acid/PhOH under reflux then resulted in de-methylation followed by a ring-opening/ring-
closing isomerisation to provide compound 2 (R=2'-OH).  
 
37 H H H H H -56.24 33.30 -4.82 28.48 -13.64 -14.12    
  43* H CH3 H H H -57.77 34.64 -4.86 29.78 -14.52 -13.47 
  52* H H CH3 H H -50.53 28.42 -4.59 23.83 -14.68 -12.01 
a c.f. Eq.’s (1) and (2). Chrysin is highlighted in bold italics and the eight ligands selected for synthesis 




Scheme 1. Synthesis of the eight substituted 5,7-dihydroxyflavones analogues tested.  
 
2.3 Kinetics 
The inhibitory potency of 1, 2, 9, 10, 11, 20, 43 and 52 was assessed against human liver GPa 
(hlGPa; the pharmaceutical target), and rmGPa and rmGPb for comparison reasons to the 
structural studies (performed with rmGPb). Since the Ki of quercetin has not been reported and 
the Ki of chrysin was reported for the glycogen breakdown [16], we determined the inhibition 
constants for these compounds against all three enzymes for comparison. All results are 
presented in Table 2. Quercetin displays a preference for rmGPa over rmGPb, as suggested 
previously by the IC50 values [13], but it is not as significant as implied (2-fold vs 5-fold). 
Nevertheless, quercetin is almost equipotent for rmGPa and hlGPa. Compounds 1, 2, and 10 
displayed only 14-27% inhibition at 100 μM for rmGPb and thus, we did not perform any 
further kinetic studies due to the observed weak inhibition.  
To establish the binding site of 9, 11, 20, 43 and 52, the inhibition behaviour of the five 
compounds was investigated with respect to caffeine (inhibitor site) and AMP (allosteric site). 
The kinetic data were analysed by Dixon plots from which the interaction constant (α) between 
multiple inhibitors can be estimated [39].  Thus, with varying concentrations of caffeine and 9, 
11, 20, 43 or 52, and constant concentrations of AMP (1 mM) and substrate (Glc-1-P; 20 mM) 
the Dixon plots, yielded a pattern of parallel lines (interaction constant approaches infinity), 
indicating that the binding of 9, 11, 20, 43 or 52 and caffeine is mutually exclusive (i.e. each 
one competes with caffeine for the same binding site) [39]. Similar experiments with AMP and 
constant concentrations of Glc-1-P (2.5 mM) yielded intersected lines in the Dixon plots, 
signifying that 9, 11, 20, 43 or 52 and AMP are not mutually exclusive (each of the inhibitors 
and AMP can simultaneously bind at the enzyme) [39]. These experiments indicated that all of 
the compounds (9, 11, 20, 43 and 52) bind to the inhibitor binding site. Compounds 11, 20 and 
43 are significantly more potent inhibitors than quercetin and chrysin, with Ki values in the 
range of lower μM (< 4 µM for all isoforms), while 9 is equipotent to chrysin (Table 2). 52 is 
more potent than quercetin but less potent than chrysin. 43 is the most potent of the designed 
compounds and the second most potent inhibitor reported for the inhibitor site of GP, while 11 
and 20 are almost equipotent and also among the most potent compounds discovered to date. 
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We then investigated whether the binding of the most potent inhibitor 43 to GPb interacts with 
that of glucose, like caffeine [40] which displays an interaction constant α=0.2. Initial velocity 
studies were performed by varying 43 and glucose concentrations at fixed concentrations of 
the substrates Glc-1-P (2.5 mM) and glycogen (0.2%). Plotting 1/v vs glucose concentration 
for various 43 concentrations yields a set of lines intersecting at the left of the y axis (Fig. S4). 
The binding of 43 interacts with glucose in a synergistic manner (α = 0.65).  Thus, 43 and 
glucose are able to bind to the enzyme at the same time [39], while each compound promotes 
the binding of the other, like caffeine and glucose [40] or ellagic acid and glucose [41].  
Comparing the phenyl B ring substitutions (Table 2), it seems that a halogen atom at position 
3' confers to inhibition with chlorine being the best, followed closely by fluorine, but a larger 
bromine (10) diminishes inhibitory potency. Position 4' seems to have a significant impact, and 
a fluorine atom at this position increases potency (11 and 20), while a methyl group (52) has a 
somewhat negative effect, but again a bromine diminishes potency (1).  Finally, a single methyl 
group at the 3' (or 5') position for 43 leads to the most potent inhibitor of all compounds studied 
here. The inhibitory potency of the compounds seems to follow the same pattern for the three 
enzymes (i.e. Ki values for hlGPa > rmGPa > rmGPb). 
 
Table 2. The inhibitory potency the compounds studied here for glycogen phosphorylases. The 
crystallographic atom numbering is shown in the inhibitors. 
Compound 
Ki [µM] 
rmGPb rmGPa hlGPa 
Quercetin 
 












































































































































11.40 ± 0.41 17.79 ± 2.37 21.36 ± 0.98 
 
2.4 X-ray Crystallography 
The crystal structures of rmGPb in complex with 20, 43 and 52 were determined to elucidate 
the structural basis for their strong inhibition potency. Rabbit muscle and human liver GP share 
97% sequence homology and both enzymes are fully conserved in terms of sequence and 
structure at the inhibitor binding site, thus any structural analysis on rmGPb can also apply for 
hlGPa. All three compounds were found bound, as expected, at the inhibitor site of the enzyme 
with all their atoms well defined within the electron density maps (Fig. 4). All three inhibitors 
bind very similar. Their binding modes are also similar to those of chrysin [16] and flavopiridol 
[21]. The RMSD of 0.8 Å between the free rmGPb structure and those of 20, 43 and 52 
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complexes with GPb, for all atoms of well-defined residues (18-249, 262-312, 326-829), 
indicates that the binding of the inhibitors does not trigger any significant conformational 
change. 
 
Figure 4. The Phenix polder omit difference electron density maps [42] of the ligands at the 
inhibitor site. Maps are contoured at 3.0 σ while the final models of the inhibitors are shown. 
The A and C rings (Table 2) are packed between the aromatic side-chain phenyls of Phe285 
and Tyr613 engaging in π-stacking (parallel) interactions. Para-fluorine atom of 20 is at 
distances of 3.1 and 3.2 Å from Arg770 (NH1) and Glu382 (OE2), respectively, forming two 
fluorine bonds [43]. In all of the three inhibitor complexes, the hydroxyl group (O4) of the 
inhibitor molecule (Table 2), engages in two water mediated interactions with the main chain 
nitrogen atoms of Pro611 and Gly612, while the carbonyl oxygen (O7) forms two water 
mediated interactions with the main chain carbonyl oxygen and nitrogen of Asp283 (Fig. 5). 
Overall, 20 is involved in 101 (58 nonpolar/nonpolar, 6 polar/polar, 37 nonpolar/polar) van der 
Waals interactions mainly with Phe285 and Tyr613 (64 contacts), and with Asn282, Glu382, 
His571, Ala610, Gly612, and Arg770. 43 forms 91 (58 nonpolar/nonpolar, 4 polar/polar, 29 
nonpolar/polar) van der Waals interactions mainly with Phe285 and Tyr613 (64 contacts), and 
with Asn282, Asn284, Glu382, Glu572, Ala610, Gly612, and Arg770. 52 engages in 89 (55 
nonpolar/nonpolar, 4 polar/polar, 30 nonpolar/polar) van der Waals interactions mainly with 
Phe285 and Tyr613 (59 contacts), and with Asn282, Asn284, Glu382, His571, Glu572, Ala610, 
Gly612, Arg770, and Phe771 (Fig. 5). The solvent accessibilities of the free 20, 43 and 52 are 
432, 450, and 448 Å2, respectively. When bound these values become 83, 88, and 91 Å2 
indicating that approximately 80% of their surface area becomes inaccessible to the solvent. 
The greatest contribution comes favorably from the non-polar rmGPb residues that contribute 
77%, 81%, and 86% of the protein surface which becomes inaccessible upon binding of 20, 43 
and 52, respectively. The fluorine atom of 20 is involved in 7 (2 polar/polar, 5 polar/non-polar) 
van der Waals interactions with Glu382, Arg770, and Phe771. The methyl group of 43 and 52, 
is involved 4 (2 polar/polar, 2 polar/nonpolar) and 5 (3 polar/polar, 5 polar/nonpolar) van der 
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Waals interactions, respectively with Asn284, Leu380 and Glu382 (43) or Glu382, Arg770, 




Figure 5. Stereo diagrams of the interactions of the ligands 20, 43 and 52 at the inhibitor site. 
The inhibitor molecules are shown as thick bonds, water molecules as cyan spheres and 
hydrogen bonds as dashed lines and van der Waals interactions of the B ring as mesh cloud.  
Comparative structural analysis of the three inhibitor complexes reveals that while 20 and 43 
bind at the same location within the inhibitor binding site of rmGPb the location of 52 differs 
by approximately 0.4 Å, and 52 is more exposed to the solvent (or less buried within the protein 
structure). The significant difference between the inhibitory potencies of 20 and 52 (Table 1) 
might be attributed to the two fluorine bonds and the 12 additional van der Waals interactions 
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of 20 with respect to the interactions of 52. Although, 20 forms two fluorine bonds and 10 van 
der Waals interactions in addition to those of 43, both inhibitors are almost equipotent (Kis 2.3 
and 1.0 μM, respectively). The presence of the fluorine in 20 triggers a small but significant 
conformational change of Glu382 (RMSD between the two conformations is 1.1 Å). The 
conformation adopted by the side chain of Glu382 in the rmGPb-20 complex is very similar to 
the one that it adopts in the rmGPb-52 complex (RMSD between the two conformations is 0.2 
Å). Therefore, it seems that the energy cost associated with the conformational change of 
Glu382 that accompanies the binding of 20, is compensated by the additional interactions of 
20, and hence 20 and 43 are almost equipotent.   
Superposition of three inhibitor complexes onto the rmGPb – chrysin complex [16] (Fig. 6) 
reveals that although chrysin binds very similarly to the new inhibitors, its position differs by 
0.4, 0.6, and 0.8 Å from the binding locations of 20, 43, and 52, respectively.  Upon binding to 
rmGPb, chrysin forms 96 van der Waals interactions (54 nonpolar/nonpolar, 4 polar/polar, and 
38 polar/nonpolar) and two water mediated hydrogen bonds [16]. The difference in the 
inhibitory potency between chrysin and 20 might be attributed to the fluorine bonds formed by 
the latter compound. However, the significant difference between the inhibitory potencies of 
both 43 and 52 with that of chrysin cannot be attributed to the small shift in their binding 




Figure 6. Stereo diagram of the superposition of the 20, 43, and 52 complexes onto the rmGPb-
chrysin complex [16]. 
2.5 Ex-vivo Cellular Studies  
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The efficacy of inhibitor 43 to inhibit glycogen phosphorylase was also evaluated in 
hepatocarcinoma HepG2 cells. For that purpose, HepG2 cells were precultured in high glucose 
medium (25 mM glucose), in the presence of 10 nM insulin, to activate glycogen synthesis. 
Upon inhibitor 43 treatment, cells were cultured in low glucose medium (5 mM glucose), in 
the presence of 10 nM DEX, conditions appropriate to induce glycogenolysis. Inhibitor 43 was 
checked at a concentrations range of 55 μM to 330 μM. Assessment of the enzymatic activity 
of GP in cellular extracts of HepG2 cells treated with the inhibitor 43 revealed high potency of 
inhibitor 43 to suppress GP activity, exhibiting IC50 of 70 µM (Fig. 7).   
 
Figure 7. GP inhibition by inhibitor 43 in HepG2 cells. GP activity was assayed in lysates after 
3 h incubation of the cells with 54.5, 109, 218 and 327 μΜ of 43 as described in the 
Experimental Section. The value of  IC50 was calculated as 70 ± 2.5 μΜ using the  program 
GRAFIT and the “explicit weight” function to take into account all experimental error. GP 
activity was measured at 4 different times and determined using the same method as for the in 
vitro assays.   
 
3. Conclusions 
In silico screening for GP inhibitors acting at the inhibitor site has been performed using 
chrysin as the lead compound[16] and post-docking QM/MM-PBSA binding free energy 
calculations. By retaining the 5,7-dihydroxy-4H-chromen-4-one ligand core of chrysin and 
screening for different B ring substitutions exploiting the ZINC database[26], eight candidates 
from the in silico screening were selected for synthesis with the potential for more favourable 
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interactions at the inhibitor site hydrophobic pocket. The target compounds were synthesized 
using a Baker-Venkataraman rearrangement-cyclization strategy, yielding the compounds in 
modest yields over the four step procedure. Kinetics experiments against rmGPb revealed 
compounds 11 (Ki = 1.9 µM), 20 (Ki = 2.3 µM) and 43 (Ki = 1.0 µM) among the most potent 
inhibitor site compounds known to date and more potent than any previously reported natural 
flavonoid inhibitor; multiple inhibition studies revealed binding exclusively at the site, and this 
was confirmed by X-ray crystallographic studies. The crystal structure GPb – inhibitor 
complexes revealed the interactions responsible for the observed potencies, which included 
favourable halogen B ring interactions at positions 3' and 4', but most significantly a nonpolar 
substituent (particularly methyl) at the meta position. Ex-vivo experiments for the most potent 
inhibitor (43) were also encouraging and revealed the compound to have strong inhibitory 
effects on endogenous GP activity in HepG2 cells in culture (IC50 = 70 µM). In addition, 
optimization of the pharmacological potential of the compounds can include modification of A 
and C ring properties and substituents. The increased potency of flavopiridol compared to 
chrysin with A ring substitutions supports such an approach [16, 22]. Additionally, while 
natural flavonoids have quite low oral bioavailability, flavopiridol does not [44], and together 
with the promising cellular results obtained here for 43, highlights the potential of synthetic 
flavonoid analogues in drug discovery projects such as this.  
 
4. Experimental Section 
4.1. Computational Details 
4.1.1. Protein Preparation 
The GPb protein was prepared for calculations using the solved 1.9 Å resolution co-crystallized 
complex with chrysin (PDB code 3EBO) and Schrödinger’s Protein Preparation Wizard [45]. 
The waters within 5 Å of chrysin were retained, bond orders assigned and hydrogens added, 
with protonation states for basic and acidic residues based on pKa’s at a pH of 7 calculated 
using PROPKA[46]. Subsequent optimization of hydroxyl groups, histidine protonation states 
and C/N atom flips, and side-chain O/N atom flips of Asn and Gln residues was based on 
optimizing hydrogen bonding patterns. Finally, the system was softly minimised using OPLS-
AA (2005) forcefield with the RMSD of heavy atoms kept within 0.3 Å of the crystallographic 
positions. 
4.1.2. Ligand Database Preparation 
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Using the ZINC docking database (http://zinc.docking.org/)[26], benzoyl chloride derivatives 
were filtered so that the final set of screening compounds fulfilled certain criteria (MW, HBAs, 
HBDs) among Lipinski’s ‘rule of five’ [47] for oral bioavailability [MW < 500 Da, hydrogen 
bond acceptor (HBA) ≤ 10, hydrogen bond donor (HBD) ≤ 5 and log P < 5]. The formal charge 
of the benzoyl chlorides was set to be 0 (more suitable for synthesis) and also a limit set on the 
ligand flexibility for final compounds (number of rotatable bonds ≤  5) to limit entropy loss on 
binding; a larger number of rotatable bonds (≥ 10) has also been associated with poor oral 
bioavailability [48]. Including these restrictions yielded 1169 benzoyl chloride derivatives. 
These were joined to the 5,7-dihydroxy-4H-chromen-4-one core (Figure 3) using CombiGlide 
3.9 with LigPrep [27]. This protocol yielded 1239 minimised structures including potential 
tautomers/ionization states ready for virtual screening. 
4.1.3. Docking  
Docking of ligands was performed to the prepared protein conformation from its complex with 
chrysin (c.f. 4.1.1.) (model 1) and also to an induced-fit docking (IFD) GPb model (model 2) 
of its complex with 5,7-dihydroxy-2-(naphthalen-2-yl)-4H-chromen-4-one (B ring as a 2-
naphthyl). In Stage 1 of the IFD, the 5,7-dihydroxy-2-(naphthalen-2-yl)-4H-chromen-4-one 
was docked to the inhibitor site of model 1 using Glide 6.9 with the SP scoring function and up 
to 20 poses per ligand saved. The core of the ligand (A and C ring atoms) involved in the π-
stacking was restrained to its original position (PDB code: 3EBO) using core constraints 
(tolerance 0.10 Å). The hydrophobic pocket Leu380 sidechain was temporarily trimmed in this 
stage (mutated to Ala), as well as scaling of the van der Waals radii of non-polar atoms by 0.5. 
Stage 2 was a Prime 4.2 refinement, with residues in the hydrophobic pocket refined. For Stage 
III, up to 20 protein conformations within 30 kcal/mol of the lowest-energy structure were used 
for Glide-SP re-docking. The top-ranked complex based on IFDscore was selected as model 2 
for subsequent docking. 
 
In the docking calculations of screening compounds to GPb models 1 and 2 with Glide 6.9[49] 
[50], the shape and properties of the inhibitor binding site were mapped onto grids with 
dimensions of 23.1 × 23.1 × 23.1 Å centred on the bound ligands. Standard parameters were 
applied including van der Waals scaling for non-polar atoms (by 0.8) to include modest 
‘induced-fit’ effects. Core constraints (RMSD of 0.10 Å) were applied on the A and C ring 
atoms. Docking calculations were performed using both Glide-SP and -XP, both of which 
included post-docking minimization with strain correction. All 1169 ligands were docked with 
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1 pose per ligand saved for each docking calculation, and compounds ranked by GlideScore. 
For each GP model (models 1 and 2), ligands were re-ranked by consensus scoring using a 
Simple Sum Rank [28] of the Glide-SP and –XP ranks. RMSDs between ligand atom positions 
for compounds that gave both SP and XP results were calculated to determine if similar 
(consensus) poses for were obtained [30]. A RMSD cut-off < 1.0 Å was applied for consensus 
pose agreement and retention of ligands. Additionally, ligands not feasible with the Baker-
Venkataraman rearrangement and/or with B ring substituents considered too bulky were 
filtered. Based on this process, the top 200 ligands for each of the two GPb conformation 
models 1 and 2 proceeded to the QM/MM-PBSA binding free energy calculations.  
4.1.4. QM/MM-PBSA Calculations 
Glide-SP poses for the top 200 ligands from each GPb model for docking were used directly 
as input for QM/MM-PBSA calculations. Binding free energies were calculated as the 
difference in energies between the bound and the unbound states of the protein-ligand 
complexes using Eq. (1).  
∆𝐺𝑏𝑖𝑛𝑑 = ∆𝐸𝑄𝑀/𝑀𝑀 + ∆𝐺𝑠𝑜𝑙𝑣 − 𝑇∆𝑆𝑀𝑀                    Eq. (1) 
𝐸𝑄𝑀/𝑀𝑀 and  𝑆𝑀𝑀 represent the total molecular mechanics energy (internal, electrostatic and 
van der Waals) and an entropy estimate, respectively; 𝐺𝑠𝑜𝑙𝑣, the solvation free energy.  DFT 
with the M06-2X functional[51] and the LACVP*+ basis set [52, 53] was used for the QM 
region (ligand, Phe 285 and Tyr 613 sidechains) and the rest of the protein was described using 
MM with the OPLS-AA(2005) forcefield [54]. Effectively, the MM region polarizes the QM 
region, with electrostatic effects between the MM point charges and the QM wavefunction, and 
the van der Waals interactions between QM and MM atoms accounted for.[54] No cut-off for 
non-bond interactions was employed. Corrections for basis set superposition error (BSSE) were 
not included given that the key QM interaction region atoms were the same for all ligands 
(rings A and C with Phe285 and Tyr613) and resulting cancellation of errors [16]. Additionally, 
while the magnitude of BSSE is dependent on intermolecular distance [55], the core constraints 
employed in the docking phase counteracted this effect. Bulk solvation effects were included 
using Poisson-Boltzmann Surface Area (PBSA) [56], with the default solute (internal) 
dielectric constant of 1.0 employed. The ∆𝐺𝑠𝑜𝑙𝑣 term was calculated as two components: 
                                              ∆𝐺𝑠𝑜𝑙𝑣 =   ∆𝐺𝑃𝐵
𝑠𝑜𝑙𝑣 + ∆𝐺𝑆𝐴





𝑠𝑜𝑙𝑣 account for the polar and non-polar (proportional to changes in 
solvent accessible surface areas) contributions, as described previously [34]. Meanwhile, an 
estimate for the loss of ligand entropy (∆𝑆𝑀𝑀) on binding was calculated using MM with the 
OPLS-AA(2005) forcefield [54] and the Rigid Rotor Harmonic Oscillator (RRHO) 
approximation. Using this method, the change in vibrational, rotational and translational 
entropy of the ligands on binding was considered. QM/MM-PBSA calculations were 
performed using QSite 6.9 [49]; RRHO calculations using MacroModel 11.0 [49].  
The ∆𝐺𝑏𝑖𝑛𝑑 values of ligands from both protein models (model 1 and 2) were compared and 
the best  ∆𝐺𝑏𝑖𝑛𝑑 value taken, together with its receptor-ligand complex. Ligands were ranked 
by ∆𝐺𝑏𝑖𝑛𝑑 values and those with a value < -11 kcal/mol considered further.  A Prime 4.2 [49] 
minimization was used to refine the corresponding protein-ligand complexes using default 
settings that included the OPLS3 forcefield [57] and VSGB solvation model [58]. Sidechains 
of residues surrounding the hydrophobic pocket (Asp283, Asn284, Glu382, Leu380, His571, 
Glu572, Tyr573, Arg770 and Phe771) together with the ligands were refined during this 
process, but flavonoid rings A and C constrained to maintain the orginal π-stacking distances 
with Phe285 and Tyr613. Final QM/MM-PBSA binding free energies were determined using 
the Prime output complexes as input, employing the same settings as before.  
4.2 – Synthetic Methods 
General procedure for the synthesis of 1, 9, 10, 11, 20, 43 and 52 
2’-Hydroxy-4’,6’-dimethoxyacetophenone (1 eq.) was added to the required benzoyl chloride 
(1.1 eq.) dissolved in dichloromethane (0.1M). 4-Dimethylaminopyridine (0.1 eq.) and 
triethylamine (1.5 eq.) were added and the reaction was allowed to stir for 24 hours under a 
nitrogen atmosphere. Upon completion (TLC – EtOAc, petroleum ether mixtures) the product 
was acidified with HCl and the organic layer was washed with distilled water, brine and dried 
(MgSO4). The solution was evaporated in vacuo leaving a crude solid. The crude solid was 
dissolved in dry THF (0.1M) and NaH (60% in mineral oil, 1.0 eq.) was added and the reaction 
was heated at reflux for 20 hours. Upon completion (TLC – EtOAc, petroleum ether mixtures) 
the solution was washed with HCl and extracted with EtOAc. The organic layer was washed 
with distilled water, brine and dried (MgSO4). The solution was evaporated in vacuo leaving a 
crude solid. The crude solid was suspended in conc. H2SO4 and acetic acid and this mixture 
was allowed to stir at reflux for 15 hours. After allowing to cool, the solution was poured onto 
an ice/water slurry and the resulting crystalline solid was collected using vacuum filtration. 
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The crude solid was suspended in HBr (47-49%) and glacial acetic acid and this mixture heated 
at reflux for 40 hours. After allowing to cool, the solution was poured onto an ice/water slurry, 
and following isolation and purification by flash column chromatography, yielded the title 
compound as a pure solid. 
 
Procedure for the synthesis of 2 
 
2,4,6-Trimethoxybenzoic acid (1.1 g, 5.2mmol) was dissolved in dichloromethane (65 mL), 
the reaction flask was purged with nitrogen for 10 minutes and then oxalyl chloride (0.50 mL, 
5.7 mmol) was added along with 2 drops of dimethylformamide. The mixture was allowed to 
react and the progress was monitored by TLC (50% EtOAc in petroleum ether) over the period 
of an hour until complete. The solvent was removed in vacuo to yield a viscous yellow oil (1.4 
g, 6 mmol). The crude product was dissolved in dichloromethane (50 mL) and 2’-
hydroxyacetophenone (0.66 mL, 5.5 mmol) was added along with triethylamine (1.1 mL) and 
4-dimethylaminopyridine (70 mg) and the reaction was allowed to progress overnight at room 
temperature. The organic layer was washed with NaOH (2 x 25 mL), water (2 x 25 mL) and 
brine (30 mL), and the solvent was removed in vacuo to yield a viscous yellow oil (1.8 g, 5.4 
mmol). The flask containing the crude material was purged with nitrogen for ten minutes 
followed by the addition of anhydrous tetrahydrofuran (50 mL), followed by NaH (60% in 
mineral oil, 0.22 g, 5.4 mmol) and the reaction heated at 66 °C for 20 hours. The solution was 
acidified with HCl (250 mL) to yield a pale yellow crystalline precipitate by vacuum filtration 
(1.12 g, 3.4 mmol). Flash column chromatography (SiO2; ethyl acetate:petroleum ether) 
yielded the desired rearranged product (0.8 g, 2.5 mmol). H2SO4 (5 mL) was added along with 
CH3COOH (60 mL) and this was heated to reflux for 6 hours until completion, as determined 
by TLC. The solution was poured over an ice/water slurry to yield cream-like crystals (0.2 g 
0.64 mmol). Hydroiodic acid (5 mL) was added to these crystals along with phenol (3.21 g) 
and this mixture was heated to 120 °C (bath temperature) for 2 hours. The solution was then 
poured over an ice/water slurry (300 mL) to yield a pale-cream crystalline solid (20 mg, 0.07 
mmol). 
 
4.3 – Kinetics Measurement  
rmGPb was purified from rabbit skeletal muscles following the protocol developed by 
Fischer and Krebs [59], while hlGPb was produced as described previously [60]. rmGPa and 
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hlGPa were prepared by phosphorylation of rmGPb and hlGPb, respectively, using a truncated 
form of the γ (catalytic) subunit of rabbit skeletal muscle phosphorylase kinase [61]. Kinetic 
studies were performed at 30 °C in the direction of glycogen synthesis using the method by 
Saheki et al. [62] for the determination of the released orthophosphate anions. 3 µg/mL rmGPb, 
rmGPa, or 1 µg/mL hlGPa were assayed following an established protocol described 
previously [63] and various concentrations of inhibitors. All inhibitors were treated as allosteric 
inhibitors (do not obey Michaelis-Menten model) and hence Hill plots were produced (Figures 
S1-S3).  Inhibition constant (Ki) values were then calculated from the intercept to horizontal 
axis of the plot of KM(app.) vs [inhibitor] using the non-linear regression program GRAFIT [64]. 
 
4.4 – X-ray Crystallography  
rmGPb crystals were grown by the batch method as described previously [63]. X-ray 
crystallographic binding studies were performed by diffusion of 20 (10 mM; 38 h), 43 (10 mM; 
24 h), and 52 (10 mM; 47 h) solution in the crystallization media supplemented with 25% (v/v) 
DMSO in preformed rmGPb crystals at room temperature prior to data collection. X-ray 
diffraction data were collected using a Cu X-ray microfocus source (Oxford Diffraction 
SuperNova) equipped with a 4-kappa goniometer and the ATLAS CCD (135 mm) detector at 
room temperature. X-ray data processing was performed by the program CrysalisPro (Agilent 
Technologies UK Ltd.) [65]. Scaling and merging of intensities were performed by Aimless 
and the optimum resolution was selected based on the CC1/2 criterion [66]. Crystallographic 
refinement of the complexes was performed by maximum-likelihood methods using REFMAC 
[67]. The starting model employed for the refinement of the complexes was the structure of T 
state rmGPb in complex with a C-β-D-glucopyranosyl triazole inhibitor after the removal of 
the ligand [68]. Ligand molecule coordinates and topologies were constructed using AceDRG 
[69] within Coot [70] and they were fitted to the electron density maps after adjustment of their 
torsion angles. A summary of the data processing and refinement statistics for the inhibitor 
complex structures is given in Table 3. The validity of the refinement procedure was checked 
using the PDB_REDO server [71]. As there were more than five reflections per atom available, 
both an isotropic and an anisotropic B-factor model were considered, and the isotropic B-factor 
model was selected based on the Hamilton R ratio test. A TLS model for grouped atom 
movement with one TLS group was used. The stereochemistry of the protein residues was 
validated by MolProbity [72]. Accessibility surfaces were calculated by the NACCESS 
program [73]. Figures were prepared with the CCP4 Molecular Graphics program [74]. The 
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coordinates of the new structures have been deposited with the RCSB Protein Data Bank [75] 
with codes presented in Table 3. 
 
Table 3. Summary of the diffraction data processing and refinement statistics for the rmGPb 
complexes. Values in parentheses are for the outermost shell. 
rmGPb complex 20 43 52 
Data collection and processing statistics 
Resolution (Å) 13.74 - 2.33 13.67 - 2.38 13.68 – 2.40 
Outermost shell (Å) 2.42 - 2.33 2.47 - 2.38 2.49 – 2.40 
Reflections measured 175524 200647 164680 
Unique reflections 38529 (3446) 34581 (3009) 34314 (3151) 
Multiplicity 4.6 (3.1) 5.8 (4.3) 4.8 (3.4) 
Rmerge 0.085 (0.596) 0.095 (0.570) 0.101 (0.623) 
Completeness (%) 92.6 (80.3) 90.1 (75.7) 91.2 (80.2) 
<I/σI> 10.7 (1.7) 11.3 (1.9) 10.7 (1.4) 
CC1/2 0.991 (0.768) 0.995 (0.840) 0.988 (0.754) 
Refinement statistics 
Rcryst 0.164 (0.256) 0.157 (0.238) 0.168 (0.264) 
Rfree 0.212 (0.294) 0.211 (0.244) 0.211 (0.301) 
No of solvent molecules 241 227 244 
r.m.s. deviation from ideality in 
bonds (Å) 0.005 0.004 0.003 
angles (°) 1.3 1.2 0.9 
Average B factor (Å2) 
Protein atoms 28.8 31.5 27.1 
Solvent molecules 29.1 29.2 24.2 
Inhibitor atoms 49.7 41.4 50.7 
PDB entry 6Y5O 6Y55 6Y5C 
 
 
4.5 – Ex-vivo Experiments 
Assessment of the efficacy of the potent GP inhibitors to suppress endogenous GP activity in 
hepatocarcinoma HepG2 cells was performed as previously described [76]. Briefly, human 
HepG2 hepatocarcinoma cells were maintained in Dulbecco’s modified Eagle medium 
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(DMEM), containing 25 mM glucose 10% FBS, 2 mM glutamine, and penicillin/streptomycin, 
in a humidified atmosphere with 5% CO2, at 37 °C. For GP activity assessment, cells were 
seeded in 60 mm culture dishes at a density of 1.5 X 106 cells per dish. After cell attachment 
(16-18 h), the medium was replaced by serum-free medium containing 10 nM dexamethasone, 
25 mM glucose, and 10 nΜ insulin, and cells were further incubated for 16-18 h to replete 
glycogen stores. Cells were then incubated in the absence and presence of 43 at a concentration 
range of 54.5 to 327 μΜ, in serum-free medium supplemented with 5 mM glucose and 10 nΜ 
dexamethasone (low-glucose growth medium) for 3 h. Subsequently, cells were washed in 
phosphate buffer, harvested, centrifuged at 700 X g for 5 min. Cell pellets were resuspended 
in 20 mM Tris pΗ 7.5, containing 0.05% Triton and supplemented with 1 mM PMSF. Then, 
cell lysates were sonicated followed by centrifugation at 12,000 X g at 40 C for 15 min. GP 
activity was assessed in cleared lysates as described above.  Glycogen (1% w/v) and 20mM 
Glc-1-P were added to the lysates for the assay while GP activity values were normalized 
against total protein amount, for each condition. The IC50 value of inhibitor 43 was calculated 
by the % GP activity vs inhibitor concentration diagram using the nonlinear regression program 
GRAFIT [64].   
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